Prognostic significance of tumor regression grading following preoperative chemoradiotherapy for rectal cancer in the CAO/ARO/AIO-04 randomised trial

被引：0
|
作者：
Roedel, C. [1 ]
Fietkau, R. [2 ]
Hohenberger, W. [3 ]
Hothorn, T. H. [4 ,5 ]
Wolff, H. A.
Stroebel, P. [6 ]
Hess, C. F. [5 ]
Graeven, U. [7 ]
Fokas, E. [8 ]
Arnold, D. [9 ]
Liersch, T. [10 ]
Ghadimi, M. [10 ]
Sauer, R. [2 ]
Wittekind, C. [11 ]
机构：
[1] Goethe Univ Frankfurt, Dept Radiotherapy & Radiat Oncol, D-60054 Frankfurt, Germany
[2] Univ Erlangen Nurnberg, Dept Radiat Therapy, D-91054 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Dept Surg, D-91054 Erlangen, Germany
[4] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland
[5] Univ Med Ctr Gottingen, Dept Radiotherapy, Gottingen, Germany
[6] Univ Med Ctr Gottingen, Inst Pathol, Gottingen, Germany
[7] Kliniken Maria Hilf GmbH Monchengladbach, Dept Hematol Oncol & Gastroenterol, Monchengladbach, Germany
[8] Goethe Univ Frankfurt, Dept Radiotherapy & Oncol, D-60054 Frankfurt, Germany
[9] Tumor Biol Ctr Freiburg, Freiburg, Germany
[10] Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany
[11] Univ Leipzig, Inst Pathol, D-04109 Leipzig, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V-01-03
引用
收藏
页码：S4 / S5
页数：2
相关论文
共 50 条
  • [1] Tumor Regression Grading in the CAO/ARO/AIO-04 phase 3 trial in locally advanced rectal carcinoma
    Fokas, E.
    Ghadimi, M.
    Fietkau, R.
    Stroebel, P.
    Hartmann, A.
    Sauer, R.
    Liersch, T.
    Hothorn, T.
    Wittekind, C.
    Roedel, C.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S170 - S171
  • [2] Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer: Results of the CAO/ARO/AIO-04 multicentre, open-label, randomised, phase 3 trial
    Fokas, E.
    Stroebel, P.
    Fietkau, R.
    Ghadimi, M.
    Liersch, T.
    Grabenbauer, G.
    Hartmann, A.
    Kaufmann, M.
    Sauer, R.
    Graeven, U.
    Hoffmanns, H.
    Raab, H-R
    Hothorn, T.
    Wittekind, C.
    Roedel, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S31 - S31
  • [3] Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial
    Kosmala, Rebekka
    Fokas, Emmanouil
    Flentje, Michael
    Sauer, Rolf
    Liersch, Torsten
    Graeven, Ullrich
    Fietkau, Rainer
    Hohenberger, Werner
    Arnold, Dirk
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Stroebel, Philipp
    Staib, Ludger
    Grabenbauer, Gerhard G.
    Folprecht, Gunnar
    Kirste, Simon
    Uter, Wolfgang
    Gall, Christine
    Roedel, Claus
    Polat, Bulent
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 281 - 290
  • [4] Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial
    Diefenhardt, Markus
    Martin, Daniel
    Ludmir, Ethan B.
    Fleischmann, Maximilian
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Kosmala, Rebekka
    Polat, Bulent
    Friede, Tim
    Minsky, Bruce D.
    Roedel, Claus
    Fokas, Emmanouil
    CANCERS, 2022, 14 (18)
  • [5] Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial
    Hofheinz, R. -D.
    Arnold, D.
    Fokas, E.
    Kaufmann, M.
    Hothorn, T.
    Folprecht, G.
    Fietkau, R.
    Hohenberger, W.
    Ghadimi, M.
    Liersch, T.
    Grabenbauer, G. G.
    Sauer, R.
    Roedel, C.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1793 - 1799
  • [6] Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
    Roedel, Claus
    Liersch, Torsten
    Becker, Heinz
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Graeven, Ullrich
    Arnold, Dirk
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Suelberg, Heiko
    Wittekind, Christian
    Potapov, Sergej
    Staib, Ludger
    Hess, Clemens
    Weigang-Koehler, Karin
    Grabenbauer, Gerhard G.
    Hoffmanns, Hans
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Duewel, H.-J.
    Bechstein, W. O.
    Gog, C.
    Boettcher, H.-D.
    LANCET ONCOLOGY, 2012, 13 (07): : 679 - 687
  • [7] Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial
    Fokas, Emmanouil
    Liersch, Torsten
    Fietkau, Rainer
    Hohenberger, Werner
    Beissbarth, Tim
    Hess, Clemens
    Becker, Heinz
    Ghadimi, Michael
    Mrak, Karl
    Merkel, Susanne
    Raab, Hans-Rudolf
    Sauer, Rolf
    Wittekind, Christian
    Roedel, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15) : 1554 - 1562
  • [8] Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial
    Diefenhardt, Markus
    Hofheinz, Ralf-Dieter
    Martin, Daniel
    Beissbarth, Tim
    Arnold, Dirk
    Hartmann, Arndt
    von Der Gauein, Jens
    Gruetzmann, Robert
    Liersch, Torsten
    Stroebel, Philipp
    Grabenbauer, Gerhard G.
    Rieger, Michael
    Fietkau, Rainer
    Graeven, Ullrich
    Weitz, Juergen
    Folprecht, Gunar
    Ghadimi, Michael
    Roedel, Franz
    Roedel, Claus
    Fokas, Emmanouil
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (08) : 2282 - 2291
  • [9] NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial
    Fokas, E.
    Fietkau, R.
    Hartmann, A.
    Hohenberger, W.
    Gruetzmann, R.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Grabenbauer, G.
    Wittekind, C.
    Sauer, R.
    Kaufmann, M.
    Hothorn, T.
    Roedel, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S142 - S142
  • [10] QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04)
    Kosmala, R.
    Fokas, E.
    Flentje, M.
    Sauer, R.
    Liersch, T.
    Graeven, U.
    Fietkau, R.
    Hohenberger, W.
    Arnold, D.
    Hofheinz, R.
    Ghadimi, M.
    Raab, H.
    Stroebel, P.
    Staib, L.
    Grabenbauer, G. G.
    Folprecht, G.
    Uter, W.
    Gall, C.
    Roedel, C.
    Polat, B.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S191 - S192
12345